Polio

Sinovac announced last week that China’s National Medical Products Administration has approved its Sabin-based inactivated polio vaccine (sIPV).

In its press release, the Chinese biotech said that WHO accepted its prequalification materials in early 2020 and completed site inspections this February. If prequalified, Sinovac’s sIPV would become the second Sabin-based product to gain the status after LG Chem’s in January 2021.

The Beijing Institute of Biological Products and…

WHO released detailed notes last week from the March 22-24 virtual meeting of its Strategic Advisory Group of Experts (SAGE) on Immunization.

As in the last SAGE meeting in October 2020, the impact of the pandemic on immunization as well as guidance on Covid-19 vaccines dominated the discussion. WHO’s Immunization, Vaccines and Biologicals (IVB) department director compared the scope of Covid-19 to that of the 1918 influenza pandemic. IVB noted, however, “promising signs” of response…

The Lancet Infectious Diseases published a meta-analysis last week of studies comparing the immunogenicity of one-, two- or three-dose regimens of fractional inactivated polio vaccine (fIPV) versus full-dose IPV when used against the three polio serotypes in children age 5 and under.

The researchers reported that seroconversion following a three-dose schedule of fIPV showed “no substantial difference” from three doses of full-dose IPV, but that the full dose gives higher titers of…

An update last week to UNICEF Supply Division’s price list for inactivated polio vaccine (IPV) shows that South Korea-based LG Chem’s recently prequalified Sabin-based shot is now the lowest-cost five-dose IPV available.

LG Chem’s price is $1.75 per dose in 2021 and falls to $1.50 in 2022. Denmark’s AJ Vaccines has the next cheapest five-dose IPV at $2.45 per dose in 2021 and as low as $1.90 in 2022. Serum Institute of India’s Bilthoven-manufactured shot is 80% more costly than its…

WHO added LG Chem’s Sabin-based inactivated polio vaccine (sIPV) to its list of prequalified products last month, making the shot the first PQ’d IPV to use the safer attenuated Sabin poliovirus.

In 2014, GSK accidentally spilled 45 liters of liquid contaminated by the wild-type Salk poliovirus into a Belgian river.

The third edition of WHO’s Global Action Plan to minimize poliovirus facility-associated risk (GAP III, published in 2015) opposed new Salk IPV facilities because of…

Mentions:

In another boost for the novel type 2 oral polio vaccine (nOPV2) following WHO’s Emergency Use Listing (EUL) of it last month, The Lancet published positive Phase 2 data last week from two studies comparing nOPV2 to the monovalent type 2 oral polio vaccine (mOPV2).

The studies found that two nOPV2 candidates were equally well-tolerated in infants, children and adults, with comparable immunogenicity within each cohort. The authors of the adult study added that results from genetic…

Mentions:

Beijing-based Sinovac announced last week that the China National Medical Products Administration has approved its 23-valent pneumococcal polysaccharide (PPSV23) shot—the company’s first bacterial vaccine licensure, according to the press release.

According to lot release data, Sinovac will compete for PPSV23 market share in China against Beijing Minhai, Chengdu Institute of Biological Products, Merck and Walvax.

In other Chinese vaccine news, Shenzhen Kangtai (BioKangtai)…

Sanofi issued a press release Wednesday saying its lenders agreed to link the interest rates on two revolving credit facilities worth $9.7 billion to its goals of helping eradicate polio and achieving a 30% reduction in its carbon footprint.

Sanofi said it is “committed to fully embed sustainability in its business strategy” and that the move “pioneers sustainable finance in the pharmaceutical industry.”

The “innovative character of the transaction” lies in Sanofi’s commitment to…

WHO applied its new Emergency Use Listing (EUL) procedure to a vaccine for the first time last week, enabling countries to deploy novel type 2 oral polio vaccine (nOPV2) to combat circulating vaccine-derived poliovirus outbreaks, the press release said.

The Bio Farma-produced shot is genetically stable compared to traditional OPV2, according to the Global Polio Eradication Initiative, which also said Bio Farma is preparing 160 million doses for deployment before the end of the year.…

The Lancet published Phase 3 results last week from a Gates Foundation-funded study showing that three doses of fractional inactivated polio vaccine (fIPV) administered intradermally at 10, 14 and 36 weeks resulted in broad immunity against poliovirus type 1 and 2 and was non-inferior to the same regimen of intramuscular IPV. A two-dose schedule of fIPV was also non-inferior to two full doses of IPV, and seroconversion rates for fIPV were higher when doses were given at 14 and 36 weeks than…

Mentions: